Zacks Research Upgrades Merck KGaA (OTCMKTS:MKKGY) to “Hold”

Merck KGaA (OTCMKTS:MKKGY) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks reports.

Separately, UBS Group downgraded Merck KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 20th. Six analysts have rated the stock with a Hold rating. According to data from MarketBeat, Merck KGaA has an average rating of “Hold”.

Merck KGaA Price Performance

Merck KGaA stock opened at $33.84 on Tuesday. The stock has a market cap of $21.87 billion, a price-to-earnings ratio of 17.44, a price-to-earnings-growth ratio of 2.92 and a beta of 0.92. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.69 and a quick ratio of 1.09. Merck KGaA has a 1 year low of $23.73 and a 1 year high of $34.19. The firm has a 50-day moving average of $31.71 and a two-hundred day moving average of $30.07.

About Merck KGaA

Merck KGaA is a German science and technology company headquartered in Darmstadt. Founded in 1668, it traces its origins to a pharmacy established by the Merck family and has grown into a global business serving customers in healthcare, research and industry. It is separate from the U.S.-based Merck & Co. The company operates through three main businesses. Its Healthcare division develops and markets prescription medicines, including treatments in areas such as oncology, neurology and fertility.